Moracin M (20, 60 mg/kg, Oral gavage) reduces inflammatory response in LPS (HY-D1056) -induced acute lung injury (ALI) mouse models, decreases the total number of infiltrated cells in bronchoalveolar lavage (BAL) fluid, and significantly reduces the number of neutrophils, macrophages and dendritic cells[2].
Moracin M (20, 60 mg/kg, Oral gavage) alleviates pathological changes in lung tissue in ALI mouse models, including reduces alveolar wall thickness, increases alveolar space, and reduces inflammatory cell infiltration in lung tissue[2].
Moracin M (20, 60 mg/kg, Oral gavage) significantly inhibits NF-κB activation in the lungs in a mouse model of ALI[2].
| Animal Model: | LPS-induced acute lung injury (ALI) mouse models[2] |
| Dosage: | LPS (HY-D1056) 2 mg/kg; LPS 2 mg/kg+ Moracin M 20 mg/kg, 60 mg/kg; LPS 2 mg/kg+ Dexamethasone (HY-14648) 30 mg/kg. (n=13) |
| Administration: | Oral gavage |
| Result: | Reduced the inflammatory response in ALI mouse models and reduced the total number of cells infiltrated in bronchoalveolar lavage (BAL) fluid. The number of neutrophils, macrophages and dendritic cells was significantly decreased.
Reduced the thickness of alveolar wall, increasing alveolar space, and reduced the infiltration of inflammatory cells in lung tissue.
|
